comparemela.com

Latest Breaking News On - Nasdaq lucd - Page 2 : comparemela.com

Lucid Diagnostics Inc (NASDAQ:LUCD) Short Interest Up 5 6% in June

Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 149,900 shares, an increase of 5.6% from the June 15th total of 141,900 shares. Approximately 1.5% of the company’s shares are sold short. Based on an […]

Levin Capital Strategies L P Makes New Investment in Lucid Diagnostics Inc (NASDAQ:LUCD)

Levin Capital Strategies L.P. bought a new position in Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 36,799 shares of the company’s stock, valued at approximately $50,000. Levin Capital Strategies L.P. owned about 0.09% of Lucid […]

Lucid Diagnostics Inc to Post FY2023 Earnings of ($1 32) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:LUCD)

Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) – Research analysts at Cantor Fitzgerald reduced their FY2023 earnings estimates for Lucid Diagnostics in a research note issued to investors on Wednesday, May 17th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($1.32) per share for the year, down from their previous forecast […]

Lucid Diagnostics (NASDAQ:LUCD) PT Lowered to $4 00 at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) had its price objective lowered by Cantor Fitzgerald from $4.50 to $4.00 in a research note published on Wednesday, The Fly reports. Separately, Needham & Company LLC restated a buy rating and set a $2.60 target price on shares of Lucid Diagnostics in a report on Friday, April 21st. […]

Lucid Diagnostics (NASDAQ:LUCD) Price Target Cut to $4 00 by Analysts at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) had its price target trimmed by Cantor Fitzgerald from $4.50 to $4.00 in a report issued on Wednesday, The Fly reports. Separately, Needham & Company LLC restated a buy rating and issued a $2.60 price objective on shares of Lucid Diagnostics in a report on Friday, April 21st. Lucid […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.